ERGIC1

Across TCGA pan-cancer cohorts, ERGIC1 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of ERGIC1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ERGIC1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ERGIC1 is over-expressed in tumor, although a few such as LUSC and BLCA show the opposite, repressed pattern.

KIRC, BRCA, and LUSC are the cancer types where ERGIC1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ERGIC1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+1.317	<.001	12	view →
BRCA	All	III,IV	+1.079	<.001	8	view →
LUSC	Female	II,III,IV	−0.814	<.001	6	view →
LUAD	All	All	+0.271	.001	6	view →
HNSC	All	All	+0.343	.007	5	view →
BLCA	Male	IV	−0.567	<.001	4	view →
PRAD	All	All	+0.975	<.001	2	view →
THCA	Male	II,III,IV	−0.226	.032	2	view →
CHOL	All	All	+0.653	.028	1	view →
KICH	Female	All	−0.557	.036	1	view →
READ	All	All	−0.328	.048	1	view →
LIHC	All	All	+0.266	.031	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

ERGIC1–KIRC

Open the KIRC breakdown →